T-MAXIMUM is currently focused on late-stage malignant tumors, and its lead program for recurrent glioma has received clearance to enter Phase II clinical trials. Over the next three years, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback